N/A N=40 The Use and Reproducibility of Duplex Ultrasound to Provide Indices of Left Common Iliac Vein Diameter
May-Thurner Syndrome
Primary: Left Common Iliac Vein Diameter — 7.5; 7.7 Millimeters (mm)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=692 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
N/A N=102 Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
Phase 4 N=81 Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
Phase 3 N=806 The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome
Deep Venous Thrombosis
Primary: Incidence of Post-thrombotic Syndrome (PTS) — 44; 37 participants — p=.58
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
N/A N=116 JETi Lower Extremity Venous Thrombosis
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
N/A N=27 Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
Venous Thrombosis · Neoplasms
Primary: PTS Assessment Completion — 17 Participants
N/A N=499 ClotTriever Outcomes (CLOUT) Registry
Deep Vein Thrombosis Leg · DVT · Chronic DVT of Lower Extremity
Primary: Primary Safety Endpoint: Proportion Participants With Major Adverse Events — 15 Participants
N/A N=115 FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
N/A N=407 Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
N/A N=129 JETi Lower Extremity Arterial Thrombosis
Arterial Thrombosis
Primary: Primary Effectiveness Endpoint - Clot Removal Grade From Pre-JETi to Post-JETi - Core Lab Assessed - Per Vessel Analysis — 36; 41; 52; 93 Vessels
Phase 3 N=59 ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
Submassive Pulmonary Embolism
Primary: Reduction of RV/LV Ratio — 0.03; 0.30 Ratio
Phase 2 N=30 Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins
Acute Deep Venous Thrombosis of the Lower Extremity
Primary: Number of Participants With Restored Venous Function — 28 participants
Phase 3 N=150 Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
Pulmonary Embolism · Acute Pulmonary Embolism · Sub-massive Pulmonary Embolism
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy — 1.55; -0.42 ratio
N/A N=134 Pediatric Catheter-related Thrombosis Imaging Study
Thrombosis
Primary: Total Number of Participants Who Completed the Study-Related Ultrasound (US) and Magnetic Resonance Imaging (MRI) With and Without Contrast — 133; 113; 113; 110…
Phase 3 N=472 Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Superficial Vein Thrombosis
Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252
N/A N=8,256 Epidemiology of Thromboembolism Disease: A Cohort Study
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants
Phase 3 N=109 tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Pulmonary Embolism
Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio
N/A N=10 Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
N/A N=162 Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
N/A N=10 Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Coronary Heart Disease
Primary: Brachial Flow Velocity — 21.0 cm/sec
N/A N=18 Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism
Cardiovascular Diseases
Primary: Percentage of Thrombus Obstruction — 33; 31; 23; 22 percentage of thrombus obstruction
N/A N=692 The PEERLESS Study
Pulmonary Embolism · Pulmonary Thromboembolism
Primary: Primary Endpoint: Composite Clinical Endpoint Constructed as a 5-Component Win Ratio — 52693; 10509 Number of Wins for the group
N/A N=411 Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
N/A N=76 CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Number and Percentage of Participants With Freedom of Major Adverse Event (MAE) Rate — 72 Participants
N/A N=106 FlowTriever Pulmonary Embolectomy Clinical Study
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
Phase 1 N=8 Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Safety — 0 participants
N/A N=119 A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo Aspiration System
Lower Extremity Acute Limb Ischemia · LE ALI
Primary: Target Limb Salvage Rate — 109 Participants
N/A N=212 Midlines and Thrombophlebitis
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants